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ABSTRACT
Introduction: Soil-transmitted helminth infections are
endemic in 114 countries worldwide, and cause the
highest burden of disease among all neglected tropical
diseases. The WHO includes women of reproductive age
as a high-risk group for infection. The primary
consequence of infection in this population is anaemia.
During lactation, anaemia may contribute to reduced
quality and quantity of milk, decreasing the duration of
exclusive breastfeeding and lowering the age at
weaning. To date, no study has investigated the effects
of maternal postpartum deworming on infant or
maternal health outcomes.
Methods and analysis: A single-centre, parallel,
double-blind, randomised, placebo-controlled trial will be
carried out in Iquitos, Peru, to assess the effectiveness of
integrating single-dose 400 mg albendazole into routine
maternal postpartum care. A total of 1010 mother-infant
pairs will be randomised to either the intervention or
control arm, following inhospital delivery and prior to
discharge. Participants will be visited in their homes at 1,
6, 12 and 24 months following delivery for outcome
ascertainment. The primary outcome is infant mean
weight gain between birth and 6 months of age.
Secondary outcomes include other infant growth
indicators and morbidity, maternal soil-transmitted
helminth infection and intensity, anaemia, fatigue, and
breastfeeding practices. All statistical analyses will be
performed on an intention-to-treat basis.
Ethics and dissemination: Research ethics board
approval has been obtained from the McGill University
Health Centre (Canada), the Asociación Civil Impacta
Salud y Educación (Peru) and the Instituto Nacional de
Salud (Peru). A data safety and monitoring committee is
in place to oversee study progression and evaluate
adverse events. The results of the analyses will be
published in peer-reviewed journals, and presented at
national and international conferences.
Trial registration number: Clinicaltrials.gov:
NCT01748929.
INTRODUCTION
Background
Worldwide, over two billion people are
infected with intestinal worms (hookworm,
Ascaris and Trichuris), collectively referred to
as the soil-transmitted helminths (STHs).1
STH infections discriminate across socio-
economic strata, such that the most vulner-
able individuals, who reside in areas where
adverse health, social, and economic out-
comes predominate, carry the greatest
disease burden. The WHO and other organi-
sations consider women of reproductive age
to be a high-risk group for STH infection pri-
marily because of the anaemia that is caused
by hookworm2 and Trichuris3 (whipworm)
infections. This exacerbates the already
increasing iron requirements of pregnancy,
with iron deficiencies extending into the
early lactation period.4 More than 50% of
Strengths and limitations of this study
▪ This is the first study to evaluate the effective-
ness of postpartum deworming on maternal and
infant health outcomes.
▪ Results of this trial will provide empirical evi-
dence to inform the WHO recommendation for
deworming in women of reproductive age.
▪ A large sample size (n=1010) allows for high-
powered primary and secondary analyses.
▪ This is a single-centre trial which can affect gener-
alisability of the results to other areas with different
prevalence profiles and transmission patterns of
soil-transmitted helminth infections.
▪ The study is limited to soil-transmitted helminth
infections and does not include the other para-
sitic infections.
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pregnant women, especially in developing countries, are
estimated to be anaemic.5 During lactation, anaemia is
thought to adversely affect milk production, which can
decrease the duration of exclusive breastfeeding and
lower the age at weaning,6 and ultimately impact nega-
tively on infant growth.
Lactating women in developing countries are at risk of
suffering from a shortage of dietary fat and micronutrient
deficiencies due to a suboptimal diet and parasitic infec-
tions, including STHs, which compete for micronutrients,
like iron.7 The consequences of co-occurring malnutrition
and infection in a new mother may include an impact on
breast milk composition8and subsequently, negatively affect
the nutritional status of infants.9 STH infections can cause
reduced absorption of dietary fat leading to lower energy
intake and inadequate absorption of vitamin A. Reduced
transfer of vitamin A into breast milk may cause insufficient
vitamin A acquisition in infant liver stores, leading to
vitamin A deficiency over the first 6 months of life and
beyond.10 Although maternal iron stores do not directly
affect breast milk concentrations of iron,11 maternal
anaemia may play a role in the frequency and duration of
breastfeeding due to reduced energy levels.
To date, no study has investigated the effect of provid-
ing deworming treatment to women during the early
postpartum period on infant or maternal health out-
comes. In effect, the WHO recommendation to specific-
ally include lactating women within the high-risk group
of women of reproductive age in deworming campaigns12
is based on expert opinion and not on empirical evi-
dence. Systematic reviews on deworming have, however,
been conducted on other subgroups of women in the
reproductive age (eg, non-pregnant, non-lactating
women; pregnant women). A 2010 systematic review on
deworming in non-pregnant populations13 included two
studies of women in the reproductive age: one trial14 that
specifically excluded lactating women, and one observa-
tional study15 that included lactating women, but in
which lactation status was not ascertained. Four trials to
date16–19 have been conducted in pregnant populations,
and are summarised in three systematic reviews.20–22
None of these trials used the same intervention (ie, the
same anthelminthic and micronutrient combination) or
had the same follow-up time frame. While data from
pregnant populations are of value, given the different
nature of the interface between mother and child at the
time of deworming, it is unclear whether the results are
generalisable to lactating women.
Rationale
Malnutrition is the leading cause of mortality in children
under 5 years of age in developing countries, with over
150 million children classified as underweight, stunted
and/or wasted.23 Poor nutrition predisposes children to
infection, leading to increased risk of mortality,24 higher
risk of cognitive deficits, lower educational achievement
and lower productivity as adults,25 thus perpetuating the
poverty cycle into future generations. The health of
mothers and young children are intimately intertwined,
and the 1000-days period from conception to the age of
2 years is a crucial time in shaping the health and devel-
opment of children.25 26 It is within this critical window
when interventions can have the greatest impact on
future health throughout the entire lifespan.
Deworming has been shown to be one of the safest
and most cost-effective interventions for reducing
disease burden in endemic countries, and is the corner-
stone of prevention and control measures against STH
infections.27 There is evidence from veterinary research
in ruminants that has shown that worm infections can
negatively affect the quality of milk and impair produc-
tion.28 In addition to modifying the nutritional and
immunological composition of milk,29 worm infections
also suppress energy and protein availability prior to par-
turition,30 31 which can influence feeding behaviours.
Administration of deworming treatment has been shown
to improve milk production in cattle.32 33
The proposed deworming intervention is expected to
improve capacity for breastfeeding, and quality and
quantity of milk transfer to infants by reducing maternal
anaemia, improving appetite and increasing energy
levels. Mothers with improved nutritional status and
enhanced energy levels may be more likely to initiate
and continue exclusive breastfeeding to the 6-month
recommended time point, and beyond. Additionally,
improved maternal nutritional status may influence the
passage of certain nutrients (eg, thiamin, riboflavin,
vitamin B-6 and vitamin B-12, among others34) to breast
milk during breastfeeding. This may, in turn, improve
nutritional status of infants, and enhance their growth
and development (figure 1). Integration of deworming
into early postpartum care, therefore, has the potential
to improve health outcomes for two vulnerable popula-
tions simultaneously.
The aim of the current study is to provide rigorous
empirical evidence on the benefits and underlying bio-
logical mechanisms of maternal postpartum deworming
in STH-endemic areas in order to inform global public
health policy.
Research objectives
Primary research objective
To determine the effectiveness of maternal postpartum
deworming on mean weight gain in infants between
birth and six months of age.
Figure 1 Proposed mechanism for the effect of
soil-transmitted helminth infections on maternal and infant
health.
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Secondary research objectives
1. To determine the effectiveness of maternal post-
partum deworming on the following infant outcomes:
(A) weight and height indices (ie, z-scores for
weight-for-age, weight-for-height and height-for-age);
and (B) infant morbidity (ie, occurrence of diar-
rhoea, respiratory illness, fever, and ear infection in
the previous 2 weeks).
2. To determine the effectiveness of maternal post-
partum deworming on the following maternal out-
comes: (A) STH infection and intensity; (B) anaemia;
(C) self-reported fatigue; and (D) self-reported breast-
feeding practice.
3. To determine the effectiveness of maternal post-
partum deworming on indicators of breast milk
quality, and quantity.
METHODS AND ANALYSIS
Study design and setting
A parallel, double-blind, randomised, placebo-controlled
trial (RCT) will be used to examine the effectiveness of
integrating single-dose albendazole administration into
routine in-hospital maternal postpartum care on infant
and maternal health outcomes, in Iquitos, Peru. Iquitos
is the capital of the Department of Loreto in the
Amazon Basin of northeastern Peru. Treatment alloca-
tion will take place within one centre, Hospital Iquitos
‘Cesar Garayar Garcia’. This hospital has a catchment
area that includes individuals who reside in the poor
and highly STH-endemic district of Belén. In 2004, pre-
valences of 45% for hookworm, 60% for Ascaris and
80% for Trichuris were reported in over 1000 pregnant
women enrolled in a previous RCT.17
Interventions
All women and children included in this trial will
receive usual postpartum care (eg, examinations follow-
ing delivery, nutritional counselling, infant vaccinations,
etc), according to hospital standard of care and Ministry
of Health guidelines. In addition, the following interven-
tions with be compared.
Experimental group
A single-dose 400 mg albendazole tablet (oral deworm-
ing drug) will be given to women following delivery and
prior to hospital discharge.
Control group
A single-dose 400 mg placebo tablet (identical to the
experimental drug with respect to size, shape, colour,
taste and smell) will be given to women following deliv-
ery and prior to hospital discharge.
Eligibility criteria
Inclusion criteria
Women are eligible to participate in the trial if they
meet the following criteria: (1) they deliver at Hospital
Iquitos ‘Cesar Garayar Garcia’; and (2) they are likely to
reside in Iquitos or a neighbouring area for the next
24 months.
Exclusion criteria
Women are ineligible to participate in the trial if:
(1) they deliver twins or multiples; (2) they deliver a still-
born infant or an infant with a serious congenital
medical condition; (3) they are transferred to another
hospital prior to discharge; or if (4) they are unable to
communicate in Spanish.
Randomisation
Prior to onset of the recruitment period, a statistician
not otherwise involved in the trial will produce the
randomisation sequence using a computer-generated
permuted block design with randomly varying block
sizes of 6 and 8 with a 1:1 allocation ratio. Albendazole
and matching placebo will be packaged according to the
randomisation sequence into opaque, sequentially-
numbered envelopes by a pharmacist and a clinician not
otherwise involved in the trial, and stored in a secure
temperature-controlled pharmacy.
Outcomes
Primary outcome
The primary outcome is infant mean weight gain
between birth and 6 months of age. Infant weight gain is
thought to be the most accurate measure of breastfeed-
ing adequacy and sufficient milk transfer from mother
to breastfeeding infant.6 It is also an important indicator
of infant growth in the first year of life.35 36
Secondary outcomes
Secondary infant outcomes include weight and height
indices (ie, z-scores for weight-for-age, weight-for-height
and height-for-age) and WHO/UNICEF Integrated
Management of Childhood Illness (IMCI) indicators of
infant morbidity (ie, occurrence of diarrhoea, respira-
tory illness, fever, and ear infection) in the previous
2 weeks.37 Maternal outcomes will include the preva-
lence and intensity of STH infection (combined and by
species), anaemia, self-reported fatigue and breastfeed-
ing practice, and breast milk quality and quantity. All
secondary outcomes will be ascertained at 1, 6, 12 and
24 months following delivery.
Sample size and power calculations
The sample size is calculated based on the primary
outcome, infant mean weight gain between birth and
6 months of age. An estimate of mean weight gain was
obtained from data on children aged between 5 and
7 months residing in Belén in 2010. The estimate of
4.24 kg with a SD of 1.01 kg is the weight gain expected
in the placebo group. Previous authors have claimed
that an infant mean weight gain difference of approxi-
mately 500 g is clinically meaningful from trials on
enriched formula feeding in infants.36 38 39 However,
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since the intervention for the proposed trial is given to
women rather than infants, and since there is the possi-
bility for effect dilution (ie, treating both STH infected
and non-infected mothers), a mean weight gain differ-
ence of at least 200 g is expected between the two inter-
vention groups. This difference in infant mean weight
gain is also considered to be clinically significant.40
The sample size calculation is, therefore, based on an
expected effect size of 0.2 kg and a SD of 1.01 kg, a sig-
nificance level (α) of 0.05 and a power (1-β) of 0.80.
As informed by a previous study in the same hospital
population,41 the final sample size takes into account a
20% loss to follow-up. Based on the above specifications
and a two-sided independent t test, we estimate that
1010 participants is the total sample size needed to
declare that infant weight gain is different between inter-
vention groups.
This trial will have sufficient power to detect a difference
in proportions as low as 4% for moderate/heavy STH
intensity (control group: 6% vs experimental group:
2%),17 as well as differences in species-specific STH infec-
tion (ie, hookworm, Ascaris, Trichuris) and infant morbidity
indicators (ie, recent occurrence of diarrhoea, respiratory
illness, fever, and ear infection), since the differences in
proportions between intervention groups for these out-
comes are expected to be even larger.17 42–44 The study
will also have sufficient power to detect a clinically mean-
ingful mean difference of 0.5 in z-scores for weight-for-age,
weight-for-height and height-for-age,45 and a difference in
maternal haemoglobin levels similar to those observed in
other studies on anthelmintic administration.13 17 46
Sample size and power calculations were conducted using
PS Power and Sample Size Calculations V.3.0 (Copyright
1997 by Dupont and Plummet).
Recruitment
Enumeration of pregnant women in their second and
third trimester of pregnancy living in the study area was
carried out in December 2013 and January of 2014
using rosters of pregnant women obtained from sur-
rounding health centres and through door-to-door can-
vassing, in conjunction with the Regional Ministry of
Health activities. A two-stage approach will be used for
recruiting women into the study prior to delivery.
In stage one, research assistants will visit the homes of
women in their third trimester of pregnancy to explain
the research study, obtain informed consent from both
women and their partners, and administer the baseline
questionnaire. Women who are interested in participat-
ing in the study will be assessed for eligibility. Informed
consent will be sought at this time (figure 2).
In stage two, women presenting for delivery in the
labour room of Hospital Iquitos ‘Cesar Garayar Garcia’
will be approached by a research assistant, reminded of
the study, and asked whether they are still interested in
taking part. Research assistants will work rotating shifts,
such that at least one research assistant will be present
in the labour room at all times to recruit vaginal and
caesarean-section deliveries (ie, in-hospital data collec-
tion will be ongoing 24 h/day).
Baseline assessments
Following informed consent procedures, research assis-
tants will administer a standardised questionnaire to par-
ticipants to obtain baseline information, including
socio-demographics (eg, age, residence), obstetric and
medical history (eg, parity, pregnancy complications),
intended breastfeeding practices (eg, expected duration,
exclusivity) and environmental exposures (eg, water
source).
Following delivery, research assistants will extract birth
date from hospital registries, including APGAR scores, ges-
tational age, delivery type and presence of complications.
Treatment allocation
Mother-infant pairs are normally discharged from the
hospital within 24 h of a vaginal delivery and within 72 h
of a caesarean-section. Research assistants on duty will
bring the sequentially numbered treatment envelopes,
containing the single tablet of the randomly allocated
intervention, to the maternity ward. Once women have
their final medical examination and receive their hos-
pital discharge papers, they will be visited by a research
assistant at their bedside and receive the next numbered
treatment envelope. The research assistant will directly
observe ingestion of the tablet. Participants, research
assistants, outcome assessors, data analysts, and coinvesti-
gators will be blinded to the treatment allocation.
Outcome ascertainment
All mother-infant pairs will be visited in their home at
the specified follow-up time points by a research assist-
ant to ascertain primary and secondary outcomes
Figure 2 Flow diagram of the proposed randomised-
controlled trial, including recruitment and follow-up. Duration
of follow-up is 24 months.
4 Mofid LS, et al. BMJ Open 2015;5:e008560. doi:10.1136/bmjopen-2015-008560
Open Access
(figure 2). Data will be recorded on an application
using mobile tablets, where collection and entry occurs
in real time with automated question jump patterns, val-
idation and prompts to research assistants.
Anthropometric measurements
Weight will be measured in duplicate at birth, 1, 6, 12 and
24 months using a portable electronic scale, accurate to
the nearest 0.01 kg, calibrated daily using standard weights
(Seca 354, Seca Corp., Baltimore, USA). Length will be
measured in duplicate at birth, 1, 6, 12 and 24 months as
recumbent crown-heel length on a flat surface using a
measuring mat (Seca 417, Seca Corp., Baltimore, USA),
accurate to the nearest millimetre. Both weight and length
are measured in the unclothed infant. Head circumfer-
ence (HC) will be measured in duplicate at birth, 1, 6, 12
and 24 months using a non-stretch Teflon measuring tape
(Seca 212, Seca Corp., Baltimore, USA), accurate to the
nearest millimetre. Mid-upper arm circumference
(MUAC) will be measured in duplicate at 6, 12 and
24 months using a non-stretch measuring tape (UNICEF
S0145620), accurate to the nearest millimetre. The mean
of the first and second anthropometric measurements will
be used in the analyses.
Infant morbidity
Research assistants will administer a questionnaire to the
mothers at the 1, 6, 12 and 24 month study visits. The
first component of the questionnaire is comprised of
morbidity indicators modified from the IMCI Chart.37
Mothers will be asked about episodes of diarrhoea, fever,
cough and ear infection experienced by their infant in
the previous 2 weeks. These indicators have been previ-
ously used for research purposes in developing
countries.17 43 47
Breastfeeding practice and maternal energy levels
The second component of the questionnaire is designed
to assess current breastfeeding practices (eg, duration of
exclusive breastfeeding, timing of first introduction of
complementary foods) and maternal fatigue. Questions
on breastfeeding practice have been adapted from the
WHO indicators for assessing infant and young child
feeding practices.48 Maternal fatigue is measured using
the Multidimensional Assessment of Fatigue (MAF Basia
Belza 1993, All rights reserved)49 and the Fatigue
Assessment Scale (FAS).50
Maternal haemoglobin
Maternal haemoglobin levels will be measured by research
assistants at the 1, 6, 12 and 24-month home visits using a
HemoCue machine, accurate to within 1.5% of the gold
standard reference.51 Blood for this test will be drawn
from women by finger-prick using disposable lancets.
Maternal STH infection and intensity
Stool specimens will be obtained from women at base-
line and at 6 months of follow-up in order to assess the
prevalence and intensity of STH infections. In the case
that a woman is unable to provide a stool specimen at
the time of the visit, a small plastic container labelled
with her unique study identification code will be left
with her and a research assistant will return the follow-
ing day for collection. Stool specimens will be trans-
ferred to the laboratory where these will be analysed
using the Kato-Katz method by a trained microscopist.
This technique is recommended for the assessment of
STH prevalence and also to quantify the intensity of
infection (ie, eggs per gram of stool).52
Substudy
During initial informed consent procedures, women will
be asked if they would like to take part in a substudy to
assess breast milk quality and quantity. Of those who
agree to participate, a random sample of 200 mother-
infant pairs will be selected. Breast milk quality and
quantity will be assessed in the subsample at 1 and
6 months following delivery. Each time point will consist
of six home visits over a 2-week period, on days 1, 2, 4, 5,
14 and 15.
Breast milk quality assessments
Quality of breast milk will be assessed by collecting a
50 mL milk sample from mothers. To standardise breast
milk collection methods, every effort will be made to
collect samples between 8:00 and noon to avoid extremes
in diurnal variations.34 Women will be assisted in provid-
ing a breast milk sample with a hospital-grade electronic
breast pump. Collection will occur by pumping milk into
a presterilised tube with a leak-proof seal from the breast
from which the infant has not fed for 2 h. All milk
samples will be transferred to the local laboratory on ice.
Macronutrient assessment will be completed on the same
day of collection using the MIRIS Human Milk Analyser
(HMA, Miris, Uppsala, Sweden). This machine analyzes
the macronutrient composition of breast milk, including
fat, protein, lactose, energy and dry matter from a
1–3 mL sample in 60 s. The remainder of each sample
will be divided into two presterilised tubes and stored at
−80°C; these will then be transported on dry ice to
Ghent University (Belgium) and to the Western Human
Nutrition Research Center (WHNRC) (California) for
micronutrient and immunological assessment. Breast
milk quality indicators include: IgA, IgG, lactoferrin, lyso-
zymes, vitamins A, B1, B2, B3, B6, B12, C and D, calcium,
copper, iron, zinc, free fatty acids, triglycerides and phos-
pholipids. At 1 month following delivery, the breast milk
sample will be obtained on day 1 of the 2-week assess-
ment. At 6 months following delivery, the breast milk
sample will be obtained on day 15 of the 2-week assess-
ment (figure 3).
Breast milk quantity assessments
Quantity of breast milk transferred from the mother to the
infant will be measured using the ‘dose-to-the-mother’
deuterium-oxide turnover technique.53 54 In addition to
Mofid LS, et al. BMJ Open 2015;5:e008560. doi:10.1136/bmjopen-2015-008560 5
Open Access
optimising feasibility, efficiency and accuracy, this method
is the most appropriate because it provides an estimation
of water intake from both breast milk and non-breast milk
sources.
On day 1, a baseline 3 mL urine sample will be col-
lected from mothers and their infants. Subsequent to
urine collection, mothers will receive a preweighed 10 g
oral dose of deuterium oxide (99.8% purity), accurate
to the nearest 0.001 g. Research assistants will return to
participants’ homes to collect four urine samples from
mothers on days 2, 5, 14 and 15, and five urine samples
from infants on days 2, 4, 5, 14 and 15 (figure 3).
Mothers will be asked to provide a urine sample in a
small plastic container during the home visit. Infant
urine samples will be obtained using paediatric urine
bags. Samples will be transferred into 3 mL cryogenic
tubes and stored at –20°C. Frozen urine samples will
be transported to the Instituto de Nutrición y
Tecnología de los Alimentos (INTA) at the University of
Chile for laboratory analysis using isotope ratio mass
spectrometry.
Infant water intake from breast milk and non-breast
milk will be calculated by fitting isotope data to a model
for water turnover in mothers and infants, and transfer
of milk from mother to infant using assumptions and
equations described in previous studies.53 55 56 Breast
milk intake and total water intake will be expressed as
g/day. This measure will represent the mean grams of
breast milk transferred from mother to infant per day
during each of the two 14-day assessment periods.
Statistical analyses
Descriptive analyses
Study flow, including participant consent and confirm-
ation, recruitment, eligibility, and losses to follow-up
will be depicted in a Consolidated Standards of
Reporting Trials (CONSORT) flow diagram. Continuous
and categorical variables at baseline will be expressed as
means (with SDs) and proportions, as appropriate,
for description of the study population and to allow
for comparisons in prognostic variables between inter-
vention groups. Primary and secondary analyses will
be performed according to the intention-to-treat
principle.
Primary analysis
The primary outcome, infant weight gain (in grams),
will be compared between the two intervention groups
using a Student’s t test. In addition to estimation of
crude intervention effects, multivariable linear regres-
sion analysis will be used to compare infant mean weight
gain between intervention groups, while adjusting for
baseline covariates that were a priori determined to be
important confounders in the published literature.57
These include maternal age, parity, deworming in the
past 6 months, intention to breastfeed, and infant gesta-
tional age.58 Adjusted analyses will be reported as mean
differences and 95% CIs.
Secondary analyses
Continuous outcomes will be modelled using multivari-
able linear regression and dichotomous outcomes will
be modelled using multivariable logistic and log-linear
regression methods. Log-linear regression will be used
instead of logistic regression when the prevalence of the
outcome is high (ie, >20%), as it is more appropriate for
this situation. Secondary analyses will be adjusted for the
baseline covariates mentioned above.
Sex-specific weight-for-age, weight-for-height, height-
for-age, MUAC-for-age and HC-for-age z-scores will be
calculated using WHO Anthro software (V.3.2.2, 2011)
and macros.59 Underweight, wasting and stunting will be
defined as z-scores for weight-for-age, weight-for-height,
height-for-age, respectively of <2 SDs from the median
of the WHO reference population, according to the
WHO Child Growth Standards.60
Subgroup analyses
To evaluate the presence of potential effect measure
modification due to infant sex, birthweight, and birth
length on deworming, interaction terms will be included
in separate multivariable linear regression models with
the primary outcome, infant mean weight gain. These
analyses will examine if there appears to be effect
measure modification by sex, birthweight and birth
length, and if so, they will estimate the added value of
the intervention in potentially vulnerable subgroups.
They will also provide insight into whether deworming
can improve growth trajectories separately for boys and
Figure 3 Timeline of data collection for milk quality and quantity in random sub-sample of participants. Each milk assessment is
conducted over a 2-week period.
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girls, as well as for infants born with low birthweight and
birth length. If effect measure modification is found,
results will be reported separately by subgroup.
DISSEMINATION
Trial registration
The trial is registered with clinicaltrials.gov
(NCT01748929).
Information and informed consent
Prior to the onset of the study, meetings at health
centres and the Hospital were held to inform the staff of
the purpose of the trial, anticipated benefits and risks of
participation, and study activities.
Written informed consent documents for participation
in the trial were reviewed by the Research Ethics Boards
of the McGill University Health Centre in Canada, and
the Asociación Civil Impacta Salud y Educación and the
Instituto Nacional de Salud in Peru. This document is
written in Spanish at a basic literary level and describes
the study with respect to its aims and expected contribu-
tions, the extent of participant involvement, potential
benefits and inconveniences of participation, confidenti-
ality, and the voluntary nature of initial and continued
participation. During the informed consent procedure,
research assistants will read the consent document to eli-
gible women and their partners. At this time, women
and their partners will have the opportunity to ask ques-
tions about the trial. Those who wish to participate in
the study will be asked to provide consent by signature
or fingerprint. For mothers/fathers under the age of
18 years, assent will be obtained and informed consent
will be requested from their parent, guardian or
spouse/partner over the age of 18 years. The Instituto
Nacional de Salud in Peru requires consent from both
mothers and fathers for infant participation in RCTs.
Women who do not have a partner or whose partner is
absent for an indefinite period of time (eg, works
outside of Iquitos) will be asked to sign another docu-
ment to declare the father’s absence, in accordance with
Peruvian ethics guidelines. Following informed consent,
research assistants will administer a short 10-question
evaluation to the mothers and their partners to confirm
their comprehension of the document. If the mother/
father responds incorrectly to a statement, the research
assistant will reinforce the contents of the informed
consent document.
Trial oversight
The Trial Steering Committee consists of the principal
investigator and all coinvestigators. This committee will
review the study protocol, ensure the trial is being con-
ducted in accordance with the principles of good clin-
ical practice, and appoint three international experts
with expertise in deworming, biostatistics, or clinical trial
methodology to comprise the Data Safety and
Monitoring Committee (DSMC). The DSMC will act in
accordance with internationally recognised guidelines,
review the protocol prior to study initiation, and evaluate
study conduct and the occurrence of adverse events at
specific time points throughout the trial (ie, after 50%
and 100% of recruitment, and after the completion of
each follow-up visit).
Dissemination of results and data access
The results of this trial will be published in peer-reviewed
journals, presented at various national and international
fora, and communicated to international agencies, such
as the WHO, who have taken a leadership role in devel-
oping global health policies pertaining to deworming in
high-risk population groups. Following completion of the
study, project data will initially be used by the research
team to prepare the manuscripts and other standard sci-
entific dissemination products. The final trial data set will
be available for consultation and available via direct
requests to the principal investigator (TWG).
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